Author

Xiangyuan Xu

Observed names: X. Xu, X.P. Xu, Xiaojian Xu

Institutions: Eli Lilly (United States), Shanghai University of Traditional Chinese Medicine, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Loxo Oncology at Lilly (United States)

Observed institutions: Eli Lilly (United States), Shanghai University of Traditional Chinese Medicine, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Loxo Oncology at Lilly (United States), Crown Bioscience (China)

ORCID: 0009-0002-3165-566X

Observed ORCID: 0009-0002-3165-566X

OpenAlex ID: A5043529092

Chinese yam polysaccharide enhances anti-PD-1 immunotherapy in colorectal cancer through alterations in the gut microbiota and metabolites

2025 · Guangtao Zhang, Jiashu Pan, et al. · International Journal of Biological Macromolecules · 24

Can proline dehydrogenase—a key enzyme involved in proline metabolism—be a novel target for cancer therapy?

2023 · Xiangyuan Xu, Guangtao Zhang, et al. · Frontiers in Oncology · 24

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations

2025 · James J. Harding, Do-Youn Oh, et al. · Clinical Cancer Research · 10

Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors

2015 · Peilong Zhang, Jiaqiang Dong, et al. · Bioorganic & Medicinal Chemistry Letters · 10

Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors

2016 · Peilong Zhang, Jiaqiang Dong, et al. · Bioorganic & Medicinal Chemistry Letters · 8

Comprehensive profiling of extrachromosomal circular DNAs in colorectal cancer progression

2024 · Lu Lu, Mingjie Chen, et al. · Scientific Reports · 1

Transcriptome comparison among patients, PDX, PDO, PDXO, PDXC and cell lines

2020 · B. Mao, X. Xu, et al. · European Journal of Cancer · 1

Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations

2025 · James J. Harding, Do-Youn Oh, et al.

Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations

2025 · James J. Harding, Do-Youn Oh, et al.

269 Tubb Gene Expression in Mds Patients With and Without Leukemic Evolution: a Nested Case-control Study

2015 · Y. Ma, X.P. Xu, et al. · Leukemia Research

Works count: 10

Citation count: 78

H-index: 5

I10-index: 4